Home › Compare › CYYNF vs FCPT

CYYNF vs FCPT: Dividend Comparison 2026

CYYNF yields 909.09% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYYNF wins by $8252648.16M in total portfolio value
10 years
CYYNF
CYYNF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full CYYNF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — CYYNF vs FCPT

📍 CYYNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYYNFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYYNF + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CYYNF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYYNF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, CYYNF beats the other by $5,766,875,998,539.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYYNF + FCPT for your $10,000?

CYYNF: 50%FCPT: 50%
100% FCPT50/50100% CYYNF
Portfolio after 10yr
$4126324.13M
Annual income
$3,392,280,004,916.41/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

CYYNF
No analyst data
Altman Z
-2.7
Piotroski
0/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYYNF buys
0
FCPT buys
0
No recent congressional trades found for CYYNF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYYNFFCPT
Forward yield909.09% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$8252648.21M ✓$49.1K
Annual income after 10y$6,784,560,004,057.53 ✓$5,775.28
Total dividends collected$8138900.96M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CYYNF vs FCPT ($10,000, DRIP)

YearCYYNF PortfolioCYYNF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$101,609$90,909.09$11,401$700.92+$90.2K → CYYNF
2$972,011$863,288.79$13,064$864.84+$958.9K → CYYNF
3$8,758,157$7,718,105.75$15,051$1,072.48+$8.74M → CYYNF
4$74,364,546$64,993,317.91$17,442$1,337.22+$74.35M → CYYNF
5$595,318,755$515,748,691.06$20,340$1,677.08+$595.30M → CYYNF
6$4,495,664,203$3,858,673,134.79$23,880$2,116.57+$4495.64M → CYYNF
7$32,043,550,537$27,233,189,840.42$28,241$2,689.36+$32043.52M → CYYNF
8$215,696,715,677$181,410,116,602.38$33,660$3,442.07+$215696.68M → CYYNF
9$1,372,045,052,584$1,141,249,566,809.58$40,456$4,439.95+$1372045.01M → CYYNF
10$8,252,648,210,323$6,784,560,004,057.53$49,063$5,775.28+$8252648.16M → CYYNF

CYYNF vs FCPT: Complete Analysis 2026

CYYNF — Stock

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Full CYYNF Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this CYYNF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYYNF vs SCHDCYYNF vs JEPICYYNF vs OCYYNF vs KOCYYNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.